News
PHGE
0.3839
-5.91%
-0.0241
12 Health Care Stocks Moving In Wednesday's Intraday Session
CytomX Therapeutics stock increased by 154.6% to $4.15 during Wednesday's regular session. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 36.79%. CVRx and Mobile-health Network among the losers.
Benzinga · 4d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Akanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. NanoVibronix and Predictive Oncology were among the gainers. Losers include CVRx and NRX Pharmaceuticals.
Benzinga · 4d ago
BiomX files to sell 120.15M warrants for holders
BiomX files to sell 120.15M warrants for holders Apr. 29, 2024. BiomX Inc. (PHGE) Stock filed a prospectus related to the proposed resale of about 120. 15M warrants. This prospectus is not an offer to sell these securities.
Seeking Alpha · 6d ago
Weekly Report: what happened at PHGE last week (0422-0426)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Acrivon Therapeutics stock rose 12.3% to $10.67 during Wednesday's after-market session. The company's, Q1 earnings came out today. Amarin Corp stock moved upwards by 8.12% and Universe Pharmaceuticals stock rose 7.47% in the same session.
Benzinga · 04/24 20:31
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. Syra Health stock rose 14.96% during the session. Sage Therapeutics and Evotec were among the losers in the day's trading.
Benzinga · 04/24 12:06
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Chicken Soup for the Soul (NASDAQ:CSSE) stock is rocketing more than 68% alongside heavy pre-market trading. Tesla’s stock is surging close to 24% following its latest earnings report. Earnings reports, a reverse stock split and more are the biggest pre- market stock movers.
Investorplace · 04/24 11:37
BiomX Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Dow Jones · 04/22 10:42
HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $2 Price Target
Benzinga · 04/22 10:32
BiomX’s BX211 Phage Therapy: A Revolutionary Approach to Diabetic Foot Osteomyelitis Treatment
TipRanks · 04/22 10:16
Weekly Report: what happened at PHGE last week (0415-0419)?
Weekly Report · 04/22 09:38
BIOMX ANNOUNCES THE APPOINTMENT OF SUSAN BLUM TO ITS BOARD OF DIRECTORS
Reuters · 04/18 12:00
Press Release: BiomX Announces the Appointment of Susan Blum to its Board of Directors
BiomX Inc. Announces the Appointment of Susan Blum to its Board of Directors. Ms. Blum is the Chief Financial Officer of Melinta Therapeutics, LLC. She is also appointed to serve as a member and chair of the audit committee of the Board. BiomX is a clinical-stage company advancing novel phage therapies that target specific bacteria.
Dow Jones · 04/18 12:00
BiomX Board Governance Structure and Bylaws Updated
TipRanks · 04/15 21:32
BIOMX INC - ON APRIL 11, INCREASED THE SIZE OF THE BOARD TO EIGHT MEMBERS
Reuters · 04/15 21:21
Weekly Report: what happened at PHGE last week (0408-0412)?
Weekly Report · 04/15 09:34
Weekly Report: what happened at PHGE last week (0401-0405)?
Weekly Report · 04/08 09:36
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
NASDAQ · 04/05 13:55
Biomx Inc. at a Crossroads: Shareholder Approval Required for Convertible Securities Amid Liquidity Concerns
TipRanks · 04/05 06:00
BIOMX ANNOUNCES COMPLIANCE WITH NYSE GUIDELINES ON AUDIT OPINION DISCLOSURE
Reuters · 04/04 11:49
More
Webull provides a variety of real-time PHGE stock news. You can receive the latest news about Biomx Inc through multiple platforms. This information may help you make smarter investment decisions.
About PHGE
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).